BR112015013431A2 - anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos - Google Patents
anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenosInfo
- Publication number
- BR112015013431A2 BR112015013431A2 BR112015013431A BR112015013431A BR112015013431A2 BR 112015013431 A2 BR112015013431 A2 BR 112015013431A2 BR 112015013431 A BR112015013431 A BR 112015013431A BR 112015013431 A BR112015013431 A BR 112015013431A BR 112015013431 A2 BR112015013431 A2 BR 112015013431A2
- Authority
- BR
- Brazil
- Prior art keywords
- antigen
- monoclonal antibody
- binding fragment
- binding
- monoclonal antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
resumo anticorpo monoclonal, ou respectivo fragmento ligante de antígenos; anticorpo monoclonal humanizado ou quimérico, ou respectivo fragmento ligante de antígenos; composição farmacêutica; uso; e anticorpo monoclonal humanizado ou quimérico, ou respectivo fragmento ligante de antígenos, ou anticorpo monoclonal competidor, ou respectivo fragmento ligante de antígenos são proporcionados anticorpos monoclonais e respectivos fragmentos ligantes de antígenos que se ligam a, e inibem a atividade de, cd47, bem como anticorpos monoclonais e respectivos fragmentos ligantes de antígenos que competem com os primeiros quanto a ligação a cd47. também são proporcionadas combinações de quaisquer dos anteriores. tais compostos de anticorpos são variadamente eficazes em 1) tratamento de isquemia tecidual e lesão de isquemia-reperfusão (iri) no cenário de preservação e transplantação de órgãos, hipertensão pulmonar, doença de células falciformes, enfarte do miocárdio, derrame cerebral, e outros casos de cirurgia e/ou traumatismo em que iri é um componente da patogênese; 2) no tratamento de doenças autoimunes e inflamatórias; e 3) como agentes anticancerígenos que são tóxicos para células cancerosas suscetíveis, promovendo (aumentando) sua captação e eliminação fagocíticas, e/ou matando diretamente tais células.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261736301P | 2012-12-12 | 2012-12-12 | |
US201361833691P | 2013-06-11 | 2013-06-11 | |
PCT/US2013/074766 WO2014093678A2 (en) | 2012-12-12 | 2013-12-12 | Therapeutic cd47 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015013431A2 true BR112015013431A2 (pt) | 2017-11-14 |
Family
ID=50935081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015013431A BR112015013431A2 (pt) | 2012-12-12 | 2013-12-12 | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
Country Status (16)
Country | Link |
---|---|
US (4) | US20140363442A1 (pt) |
EP (1) | EP2931751B1 (pt) |
JP (1) | JP6572131B2 (pt) |
KR (1) | KR20150093770A (pt) |
CN (1) | CN105102479B (pt) |
AU (1) | AU2013359167B2 (pt) |
BR (1) | BR112015013431A2 (pt) |
CA (1) | CA2894439A1 (pt) |
ES (1) | ES2786083T3 (pt) |
HK (1) | HK1216647A1 (pt) |
IL (1) | IL239339A0 (pt) |
MX (1) | MX2015007446A (pt) |
PH (1) | PH12015501318A1 (pt) |
RU (1) | RU2015122228A (pt) |
SG (1) | SG11201504469XA (pt) |
WO (2) | WO2014093678A2 (pt) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3054220C (en) | 2008-01-15 | 2022-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for manilpulating phagocytosis mediated by cd47 |
US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
KR20150093770A (ko) | 2012-12-12 | 2015-08-18 | 베스쿨럭스 인코포레이티드 | 치료적 cd47 항체 |
PT2931752T (pt) | 2012-12-17 | 2019-11-20 | Trillium Therapeutics Inc | Tratamento de células de doença cd47+ com fusões sirp alfa-fc |
EP3936145A1 (en) * | 2014-07-31 | 2022-01-12 | The University Of Western Australia | A method for the identification of immunotherapy-drug combinations using a network approach |
EP3204420B1 (en) | 2014-10-10 | 2020-09-02 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods to eliminate cancer stem cells by targeting cd47 |
CA2967379A1 (en) * | 2014-11-18 | 2016-05-26 | Janssen Pharmaceutica Nv | Cd47 antibodies, methods, and uses |
EP4296278A3 (en) | 2014-12-05 | 2024-03-27 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 47 gene |
US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
CN107921121B (zh) * | 2015-03-04 | 2022-02-08 | 索伦托药业有限公司 | 结合cd47的抗体治疗剂 |
CN104804093A (zh) * | 2015-05-27 | 2015-07-29 | 江苏春申堂药业有限公司 | 一种针对cd47的单域抗体 |
WO2017035480A1 (en) | 2015-08-26 | 2017-03-02 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist |
US10221249B2 (en) * | 2015-09-10 | 2019-03-05 | Affigen, Llc | Method of making patient specific anti-idiotype antibodies |
EP3349787A4 (en) | 2015-09-18 | 2019-03-27 | Arch Oncology, Inc. | THERAPEUTIC CD47 ANTIBODIES |
GB2558131B (en) | 2015-09-21 | 2021-05-19 | Surface Oncology Inc | Anti-CD47 antibodies and methods of use |
EP3380117B1 (en) | 2015-11-27 | 2021-01-06 | Cartherics Pty. Ltd. | Genetically modified cells and uses thereof |
JP7227007B2 (ja) | 2015-12-02 | 2023-02-21 | ストサイエンシス, インコーポレイテッド | グリコシル化btla(b-及びt-リンパ球減弱因子)に特異的な抗体 |
ES2796378T3 (es) | 2016-01-11 | 2020-11-26 | Forty Seven Inc | Anticuerpos monoclonales anti-cd47 humanizados, de ratón o químicos |
US20170210803A1 (en) * | 2016-01-21 | 2017-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with combinations of immunoregulatory agents |
EP3442593A4 (en) * | 2016-04-15 | 2020-01-01 | Trillium Therapeutics Inc. | STIMULATION OF MACROPHAGES IN THERAPY BY CD47 BLOCKING |
CN106084052B (zh) | 2016-06-17 | 2019-12-27 | 长春金赛药业股份有限公司 | 抗cd47单克隆抗体及其应用 |
CN106117354B (zh) * | 2016-06-24 | 2020-01-14 | 安徽未名细胞治疗有限公司 | 一种全人源抗CD47的全分子IgG抗体及其应用 |
US11618784B2 (en) | 2016-07-19 | 2023-04-04 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD47 combination therapy |
CN114773471A (zh) | 2016-10-20 | 2022-07-22 | 天境生物科技(上海)有限公司 | 新的cd47单克隆抗体及其应用 |
WO2018075960A1 (en) * | 2016-10-21 | 2018-04-26 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
WO2018081897A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
TW201819413A (zh) * | 2016-11-28 | 2018-06-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Cd47抗體、其抗原結合片段及其醫藥用途 |
EP3345924A1 (en) * | 2017-01-10 | 2018-07-11 | Universität Duisburg-Essen | Use of cd47 antibodies |
GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
CA3051512A1 (en) * | 2017-01-26 | 2018-08-02 | Zlip Holding Limited | Cd47 antigen binding unit and uses thereof |
EP3601351A1 (en) * | 2017-03-27 | 2020-02-05 | Celgene Corporation | Methods and compositions for reduction of immunogenicity |
WO2018176132A1 (en) * | 2017-03-28 | 2018-10-04 | Trillium Therapeutics Inc. | Cd47 blockade therapy |
WO2019014398A1 (en) | 2017-07-11 | 2019-01-17 | Actym Therapeutics, Inc. | MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF |
KR102646468B1 (ko) | 2017-08-02 | 2024-03-11 | 페인스 테라퓨틱스 인코포레이티드 | 항-cd47 항체 및 이의 용도 |
WO2019034895A1 (en) * | 2017-08-18 | 2019-02-21 | Ultrahuman Four Limited | LIAISON AGENTS |
CN109422811A (zh) * | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
EA039662B1 (ru) | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Антитела, специфичные к cd47 и pd-l1 |
US11802153B2 (en) | 2017-10-18 | 2023-10-31 | Forty Seven, Inc. | Anti-CD47 agent-based ovarian cancer therapy |
AU2018358004A1 (en) | 2017-11-01 | 2020-05-28 | Hummingbird Bioscience Pte. Ltd. | CD47 antigen-binding molecules |
WO2019090355A1 (en) * | 2017-11-06 | 2019-05-09 | Children's National Medical Center | Cells expressing antibodies and methods of treatment using the same |
WO2019084692A1 (en) * | 2017-11-06 | 2019-05-09 | Trillium Therapeutics Inc. | Cd47 blockade with radiation therapy |
JP7391845B2 (ja) | 2017-12-01 | 2023-12-05 | シージェン インコーポレイテッド | Cd47抗体及びがんを治療するためのその使用 |
CN110144009B (zh) * | 2018-02-14 | 2020-01-21 | 上海洛启生物医药技术有限公司 | Cd47单域抗体及其用途 |
CN110305212A (zh) * | 2018-03-27 | 2019-10-08 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
US20210155691A1 (en) * | 2018-04-16 | 2021-05-27 | Adaerata, Limited Partnership | Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers |
CN108484770B (zh) * | 2018-05-16 | 2020-11-13 | 武汉云克隆科技股份有限公司 | 重组大鼠抗小鼠cd4单克隆抗体,制备方法和应用 |
CN110538321B (zh) * | 2018-05-29 | 2023-03-10 | 江苏恒瑞医药股份有限公司 | 一种cd47抗体药物组合物及其用途 |
CN112566662A (zh) | 2018-06-15 | 2021-03-26 | 阿库鲁斯生物科学公司 | 针对cd47的阻断抗体及其使用方法 |
CN110615841B (zh) * | 2018-06-20 | 2022-01-04 | 瑞阳(苏州)生物科技有限公司 | 抗人cd47单克隆抗体及其应用 |
JP7340591B2 (ja) | 2018-07-11 | 2023-09-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
US20210324075A1 (en) * | 2018-08-13 | 2021-10-21 | Arch Oncology, Inc. | Therapeutic cd47 antibodies |
US11242528B2 (en) | 2018-08-28 | 2022-02-08 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
WO2020043188A1 (zh) * | 2018-08-31 | 2020-03-05 | 南京圣和药业股份有限公司 | 抗cd47抗体及其应用 |
EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
WO2020114399A1 (zh) * | 2018-12-03 | 2020-06-11 | 上海开拓者生物医药有限公司 | Cd47抗体及其制备方法和应用 |
EP3936526A4 (en) | 2019-03-06 | 2023-03-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | BIFUNCTIONAL FUSION PROTEIN AND PHARMACEUTICAL USE |
US11026973B2 (en) | 2019-04-30 | 2021-06-08 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
WO2020247820A1 (en) | 2019-06-07 | 2020-12-10 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
WO2020253785A1 (en) * | 2019-06-19 | 2020-12-24 | Lepu Biopharma Co., Ltd. | Anti-cd47 antibodies and uses thereof |
KR20220024211A (ko) | 2019-06-19 | 2022-03-03 | 레푸 바이오파마 컴퍼니 리미티드 | 항-cd47 항체 및 그것의 사용 |
AU2020315598A1 (en) | 2019-07-16 | 2022-03-03 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
MX2022002613A (es) | 2019-09-03 | 2022-06-02 | Myeloid Therapeutics Inc | Metodos y composiciones para la integracion del genoma. |
AU2020342192A1 (en) * | 2019-09-03 | 2022-04-21 | Akeso Biopharma, Inc | Anti-CD47 monoclonal antibody and use thereof |
KR20220085796A (ko) | 2019-10-18 | 2022-06-22 | 포티 세븐, 인코포레이티드 | 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료 |
US20220403023A1 (en) * | 2019-10-25 | 2022-12-22 | WuXi Biologics Ireland Limited | Novel anti-cd47 antibodies and uses thereof |
US20210147568A1 (en) | 2019-10-31 | 2021-05-20 | Forty Seven, Inc. | Anti-cd47 based treatment of blood cancer |
GB201918230D0 (en) | 2019-12-11 | 2020-01-22 | Prec Therapeutics Ltd | Antibodies and their uses |
US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
MX2022007598A (es) | 2019-12-20 | 2022-09-23 | Instil Bio Uk Ltd | Dispositivos y métodos para el aislamiento de linfocitos infiltrantes de tumores y usos de los mismos. |
EP4081305B1 (en) | 2019-12-24 | 2024-09-18 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
CN115087488A (zh) | 2020-02-14 | 2022-09-20 | 震动疗法股份有限公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
WO2021190441A1 (zh) * | 2020-03-23 | 2021-09-30 | 倍而达药业(苏州)有限公司 | Cd47/人源化cd47抗体或其抗原结合片段、免疫活性片段及应用 |
CA3172449A1 (en) | 2020-03-27 | 2021-09-30 | Erik Hans MANTING | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
TW202144407A (zh) * | 2020-04-02 | 2021-12-01 | 大陸商正大天晴藥業集團股份有限公司 | 結合cd47的抗原結合多肽及用途 |
CN111635459B (zh) * | 2020-06-27 | 2021-01-15 | 广东赛尔生物科技有限公司 | 抗cd47抗体及其在治疗癌症中的应用 |
JP2023550544A (ja) | 2020-11-03 | 2023-12-01 | アールディスカバリー エルエルシー | がんおよびファゴサイトーシス不全に関連する疾患の処置のための療法 |
AU2021376354A1 (en) | 2020-11-04 | 2023-06-22 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
KR20230142828A (ko) * | 2020-11-04 | 2023-10-11 | 더 트러스티즈 오브 다트마우스 칼리지 | 허혈성 및/또는 재관류 손상의 치료/예방을 위한 vista 작용제 |
JP2023552375A (ja) | 2020-12-06 | 2023-12-15 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてcd47に結合する薬物の干渉を低減するための多量体 |
WO2022130016A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
CN116964095A (zh) * | 2021-02-19 | 2023-10-27 | 沙裴隆有限公司 | 针对cd47的单域抗体及其用途 |
KR20230157388A (ko) | 2021-03-12 | 2023-11-16 | 멘두스 비.브이. | 백신접종의 방법 및 cd47 차단의 용도 |
CN112979764B (zh) * | 2021-03-26 | 2022-08-02 | 复旦大学附属中山医院 | 特异结合人cd47分子的多肽及其用途 |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
KR20240025616A (ko) | 2021-06-23 | 2024-02-27 | 길리애드 사이언시즈, 인코포레이티드 | 다이아실글리세롤 키나제 조절 화합물 |
EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022297367A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
KR20240091056A (ko) | 2021-10-28 | 2024-06-21 | 길리애드 사이언시즈, 인코포레이티드 | 피리디진-3(2h)-온 유도체 |
CN118201941A (zh) | 2021-10-29 | 2024-06-14 | 吉利德科学公司 | Cd73化合物 |
CA3239528A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
WO2023159220A1 (en) * | 2022-02-18 | 2023-08-24 | Kenjockety Biotechnology, Inc. | Anti-cd47 antibodies |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3751908T2 (de) | 1986-07-07 | 1997-02-06 | Centocor Inc | Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen |
CA2303072A1 (en) | 1997-09-11 | 1999-03-18 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody inducing apoptosis |
US7531643B2 (en) | 1997-09-11 | 2009-05-12 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody inducing apoptosis |
CA2226962A1 (en) * | 1998-02-16 | 1999-08-16 | Marie Sarfati | Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection |
DE19813759C1 (de) | 1998-03-27 | 1999-07-15 | Gsf Forschungszentrum Umwelt | Verfahren zur Induktion einer durch NK-Zellen vermittelten Immunantwort |
US7696325B2 (en) | 1999-03-10 | 2010-04-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide inducing apoptosis |
WO2000053634A1 (fr) | 1999-03-10 | 2000-09-14 | Chugai Seiyaku Kabushiki Kaisha | Fv monocatenaire induisant l'apoptose |
JP2004513066A (ja) * | 1999-06-21 | 2004-04-30 | インカイン ファーマシューティカル カンパニー,インコーポレイティド | アンジオシジン:cys−ser−val−thr−cys−gly特異的腫瘍細胞付着受容体 |
US20010041670A1 (en) * | 1999-12-06 | 2001-11-15 | Ronit Simantov | Thrombospondin-binding region of histidine-rich glycoprotein and method of use |
EP1519735A4 (en) | 2001-12-12 | 2006-01-11 | Conforma Therapeutic Corp | ASSAYS AND DEVICES FOR DETERMINING AND MODULATING HSP90 BINDING ACTIVITY |
US20040213792A1 (en) | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
CN101133083A (zh) | 2003-11-11 | 2008-02-27 | 中外制药株式会社 | 人源化的抗cd47抗体 |
WO2006031653A2 (en) | 2004-09-10 | 2006-03-23 | Wyeth | Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates |
JP2007008895A (ja) | 2005-07-04 | 2007-01-18 | Chugai Pharmaceut Co Ltd | 抗cd47抗体とインテグリンリガンドとの併用 |
US7514229B2 (en) | 2005-09-29 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and evaluating treatment of blood disorders |
MX2008011492A (es) | 2006-03-10 | 2008-09-22 | Wyeth Corp | Anticuerpos anti-5t4 y usos de los mismos. |
WO2008043072A2 (en) | 2006-10-05 | 2008-04-10 | Biogen Idec Inc. | Cd80 antagonists for treating neoplastic disorders |
CA3163418A1 (en) * | 2006-10-06 | 2008-05-22 | Jeffrey S. Isenberg | Prevention of tissue ischemia, related methods and compositions |
AU2014201010B2 (en) | 2008-01-15 | 2016-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for manipulating phagocytosis mediated by CD47 |
CA3054220C (en) | 2008-01-15 | 2022-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for manilpulating phagocytosis mediated by cd47 |
CA2965198C (en) | 2008-01-15 | 2021-02-16 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
JP2011512332A (ja) | 2008-02-11 | 2011-04-21 | キュアー テック リミテッド | 腫瘍治療のためのモノクローナル抗体 |
KR101604515B1 (ko) | 2008-03-14 | 2016-03-17 | 알러간, 인코포레이티드 | 면역-기반 보툴리눔 독소 세로타입 a 활성 검정 |
EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
US8951527B2 (en) | 2008-08-07 | 2015-02-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Radioprotectants targeting thrombospondin-1 and CD47 |
SI2477648T1 (sl) | 2009-09-15 | 2022-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Sinergijska terapija proti CD47 za krvne rake |
WO2011083140A1 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Immunoglobulin single variable domain directed against human cxcr4 |
CN102812041A (zh) | 2010-01-21 | 2012-12-05 | 英穆尔诺基公司 | 治疗卵巢癌的组合物及方法 |
PL3789038T3 (pl) * | 2010-05-14 | 2023-01-23 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47 |
US9243057B2 (en) | 2010-08-31 | 2016-01-26 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
US20140271683A1 (en) | 2010-12-21 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor |
EP2812443B1 (en) * | 2012-02-06 | 2019-05-29 | Inhibrx, Inc. | Cd47 antibodies and methods of use thereof |
US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
CN104024276A (zh) | 2012-06-21 | 2014-09-03 | 卡姆普根有限公司 | Lsr抗体及其用于癌症治疗的用途 |
ES2784631T3 (es) | 2012-12-03 | 2020-09-29 | Novimmune Sa | Anticuerpos anti-CD47 y métodos de uso de los mismos |
KR20150093770A (ko) | 2012-12-12 | 2015-08-18 | 베스쿨럭스 인코포레이티드 | 치료적 cd47 항체 |
US9221908B2 (en) * | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
SG11201506132PA (en) | 2013-02-06 | 2015-09-29 | Inhibrx Llc | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
ES2728066T3 (es) | 2013-03-15 | 2019-10-22 | Univ Leland Stanford Junior | Métodos para la obtención de dosis terapéuticamente eficaces de agentes anti-CD47 |
CN103665165B (zh) | 2013-08-28 | 2016-02-24 | 江苏匡亚生物医药科技有限公司 | 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途 |
EP3089993A1 (en) | 2013-12-31 | 2016-11-09 | Development Center for Biotechnology | Anti-vegf antibodies and use thereof |
EP3349787A4 (en) | 2015-09-18 | 2019-03-27 | Arch Oncology, Inc. | THERAPEUTIC CD47 ANTIBODIES |
US10946042B2 (en) | 2015-12-01 | 2021-03-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for selective phagocytosis of human cancer cells |
WO2018075960A1 (en) | 2016-10-21 | 2018-04-26 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
US20190309066A1 (en) | 2017-03-22 | 2019-10-10 | Arch Oncology, Inc. | Combination therapy for the treatment of solid and hematological cancers |
EP3600393A4 (en) | 2017-03-22 | 2020-12-23 | Arch Oncology, Inc. | COMBINATION THERAPY FOR THE TREATMENT OF SOLID AND HEMATOLOGICAL MALIGNANT TUMORS |
-
2013
- 2013-12-12 KR KR1020157018026A patent/KR20150093770A/ko not_active Application Discontinuation
- 2013-12-12 AU AU2013359167A patent/AU2013359167B2/en not_active Ceased
- 2013-12-12 CA CA2894439A patent/CA2894439A1/en not_active Abandoned
- 2013-12-12 SG SG11201504469XA patent/SG11201504469XA/en unknown
- 2013-12-12 BR BR112015013431A patent/BR112015013431A2/pt not_active Application Discontinuation
- 2013-12-12 WO PCT/US2013/074766 patent/WO2014093678A2/en active Application Filing
- 2013-12-12 RU RU2015122228A patent/RU2015122228A/ru not_active Application Discontinuation
- 2013-12-12 MX MX2015007446A patent/MX2015007446A/es unknown
- 2013-12-12 EP EP13863325.0A patent/EP2931751B1/en active Active
- 2013-12-12 JP JP2015547563A patent/JP6572131B2/ja active Active
- 2013-12-12 ES ES13863325T patent/ES2786083T3/es active Active
- 2013-12-12 CN CN201380065387.2A patent/CN105102479B/zh active Active
-
2014
- 2014-06-11 US US14/302,348 patent/US20140363442A1/en not_active Abandoned
-
2015
- 2015-06-09 PH PH12015501318A patent/PH12015501318A1/en unknown
- 2015-06-10 IL IL239339A patent/IL239339A0/en unknown
- 2015-06-11 WO PCT/US2015/035345 patent/WO2015191861A1/en active Application Filing
- 2015-06-11 US US14/737,053 patent/US20150274826A1/en not_active Abandoned
-
2016
- 2016-04-14 HK HK16104306.3A patent/HK1216647A1/zh unknown
-
2017
- 2017-10-03 US US15/723,534 patent/US10676524B2/en not_active Expired - Fee Related
- 2017-10-03 US US15/723,523 patent/US10669336B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2013359167B2 (en) | 2018-08-23 |
NZ708445A (en) | 2020-10-30 |
CN105102479B (zh) | 2019-06-28 |
WO2015191861A1 (en) | 2015-12-17 |
US20140363442A1 (en) | 2014-12-11 |
US10676524B2 (en) | 2020-06-09 |
US20150274826A1 (en) | 2015-10-01 |
MX2015007446A (es) | 2015-12-07 |
AU2013359167A1 (en) | 2015-06-11 |
US10669336B2 (en) | 2020-06-02 |
HK1216647A1 (zh) | 2016-11-25 |
EP2931751A2 (en) | 2015-10-21 |
CN105102479A (zh) | 2015-11-25 |
WO2014093678A3 (en) | 2014-11-27 |
EP2931751A4 (en) | 2016-07-13 |
JP2016501892A (ja) | 2016-01-21 |
US20180051081A1 (en) | 2018-02-22 |
JP6572131B2 (ja) | 2019-09-04 |
ES2786083T3 (es) | 2020-10-08 |
KR20150093770A (ko) | 2015-08-18 |
PH12015501318A1 (en) | 2015-08-24 |
SG11201504469XA (en) | 2015-07-30 |
US20180057592A1 (en) | 2018-03-01 |
EP2931751B1 (en) | 2020-02-05 |
RU2015122228A (ru) | 2017-01-19 |
CA2894439A1 (en) | 2014-06-19 |
IL239339A0 (en) | 2015-07-30 |
WO2014093678A2 (en) | 2014-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015013431A2 (pt) | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos | |
CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
EA201170716A1 (ru) | Антитела к с-мет | |
CY1115572T1 (el) | Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου | |
MX2018007089A (es) | Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas. | |
EA201391761A1 (ru) | Анти-альфа-синуклеинсвязывающие молекулы | |
CY1115349T1 (el) | Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου | |
BR112015010360A2 (pt) | anticorpo isolado ou fragmento de ligação a antígeno do mesmo que pode se ligar especificamente ao sítio ii de uma il-6 humana, seus usos, ácido nucleico, composição, vetor, célula, e processo para produzir a mesma | |
FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
BR112013028779B8 (pt) | proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, e, uso de uma composição | |
AR069290A1 (es) | Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden | |
EA201290570A1 (ru) | Конструкты, связывающиеся с ron, и способы их использования | |
EA201270813A1 (ru) | АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ | |
EA201690567A1 (ru) | Антитела против pd1 и их применение в качестве терапевтических и диагностических средств | |
WO2013013025A3 (en) | Anti-cxcr4 antibodies and methods of use | |
AR092818A1 (es) | Anticuerpo tau humanizado | |
EA201100923A1 (ru) | Антитела человека против тканевого фактора | |
EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
BR112014029099A2 (pt) | anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende | |
EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
EP2439273A3 (en) | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics | |
EA201892184A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора | |
EA201070730A1 (ru) | Гуманизированные антитела, специфичные к фактору фон виллебранда | |
CY1120803T1 (el) | Πρωτεϊνες δεσμευσης με αντιγονο ειδικες για το συστατικο ρ αμυλοειδους ορου | |
EA201171237A1 (ru) | Антитела к dkk-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |